BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 21621926)

  • 1. Mitochondrial UCP4 and bcl-2 expression in imprints of breast carcinomas: relationship with DNA ploidy and classical prognostic factors.
    Gonidi M; Athanassiadou AM; Patsouris E; Tsipis A; Dimopoulos S; Kyriakidou V; Chelidonis G; Athanassiadou P
    Pathol Res Pract; 2011 Jun; 207(6):377-82. PubMed ID: 21621926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of EZH2, paxillin expression and DNA ploidy of breast adenocarcinoma: correlation to pathologic predictors.
    Panousis D; Xepapadakis G; Lagoudianakis E; Karavitis G; Salemis N; Koronakis N; Patsouris E; Koronarchis D; Grosomanidis D; Chryssikos G; Ntasiou P; Kyriakidou V; Athanassiadou AM; Athanassiadou P
    J BUON; 2013; 18(4):879-85. PubMed ID: 24344012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship of DNA ploidy to hormone receptor status and proliferation in invasive breast carcinoma.
    Spiethoff A; Schenck A; Bohrer M
    J Cancer Res Clin Oncol; 2000 Dec; 126(12):707-10. PubMed ID: 11153143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of Oncotype DX and TAILORx risk categories using histopathological and immunohistochemical markers by classification and regression tree (CART) analysis.
    Ingoldsby H; Webber M; Wall D; Scarrott C; Newell J; Callagy G
    Breast; 2013 Oct; 22(5):879-86. PubMed ID: 23643806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical expression of Bcl-2 protein in breast lesions: correlation with Bax, p53, Rb, C-erbB-2, EGFR and proliferation indices.
    Ioachim EE; Malamou-Mitsi V; Kamina SA; Goussia AC; Agnantis NJ
    Anticancer Res; 2000; 20(6B):4221-5. PubMed ID: 11205251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic and predictive factors of invasive ductal breast carcinomas.
    Lialiaris TS; Georgiou G; Sivridis E; Kareli D; Tripsiannis G; Papageorgiou A; Chrisafi S; Kritsi Z; Giatromanolaki A
    J BUON; 2010; 15(1):79-88. PubMed ID: 20414932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of cell cycle markers in well-differentiated lobular and ductal carcinomas.
    Soslow RA; Carlson DL; Horenstein MG; Osborne MP
    Breast Cancer Res Treat; 2000 May; 61(2):161-70. PubMed ID: 10942102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor growth fraction, expression of estrogen and progesterone receptors, p53, bcl-2 and cathepsin D activity in primary ductal invasive breast carcinoma and their axillary lymph node metastases.
    Kristek J; Dmitrović B; Kurbel S; Sakić K; Krajinović Z; Blazicević V; Has B; Marjanović K
    Coll Antropol; 2007 Dec; 31(4):1043-7. PubMed ID: 18217456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bcl-2 with loss of apoptosis allows accumulation of genetic alterations: a pathway to metastatic progression in human breast cancer.
    Sierra A; Castellsagué X; Escobedo A; Lloveras B; García-Ramirez M; Moreno A; Fabra A
    Int J Cancer; 2000 Mar; 89(2):142-7. PubMed ID: 10754491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation.
    Ioachim E; Kamina S; Demou A; Kontostolis M; Lolis D; Agnantis NJ
    Anticancer Res; 1999; 19(3A):2133-9. PubMed ID: 10470161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NKX3.1 is expressed in ER-positive and AR-positive primary breast carcinomas.
    Asch-Kendrick RJ; Samols MA; Lilo MT; Subhawong AP; Sharma R; Illei PB; Argani P; Cimino-Mathews A
    J Clin Pathol; 2014 Sep; 67(9):768-71. PubMed ID: 24996432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical prediction of brain metastases in patients with advanced breast cancer: the role of Rad51.
    Sosińska-Mielcarek K; Duchnowska R; Winczura P; Badzio A; Majewska H; Lakomy J; Pęksa R; Pieczyńska B; Radecka B; Dębska S; Biernat W; Jassem J
    Breast; 2013 Dec; 22(6):1178-83. PubMed ID: 24060578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apocrine ductal carcinoma in situ of the breast: histologic classification and expression of biologic markers.
    Leal C; Henrique R; Monteiro P; Lopes C; Bento MJ; De Sousa CP; Lopes P; Olson S; Silva MD; Page DL
    Hum Pathol; 2001 May; 32(5):487-93. PubMed ID: 11381366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast.
    von Minckwitz G; Sinn HP; Raab G; Loibl S; Blohmer JU; Eidtmann H; Hilfrich J; Merkle E; Jackisch C; Costa SD; Caputo A; Kaufmann M;
    Breast Cancer Res; 2008; 10(2):R30. PubMed ID: 18380893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-FDG semi-quantitative parameters and biological prognostic factors in locally advanced breast cancer.
    García Vicente AM; Soriano Castrejón A; Relea Calatayud F; Muñoz Madero V; Molina Garrido MJ; León Martín AA; Cordero García JM; Pilkington Woll JP; Chacón López-Muñiz I; Palomar Muñoz A
    Rev Esp Med Nucl Imagen Mol; 2012; 31(6):308-14. PubMed ID: 23084013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncogenes and male breast carcinoma: c-erbB-2 and p53 coexpression predicts a poor survival.
    Pich A; Margaria E; Chiusa L
    J Clin Oncol; 2000 Aug; 18(16):2948-56. PubMed ID: 10944127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up.
    el-Ahmady O; el-Salahy E; Mahmoud M; Wahab MA; Eissa S; Khalifa A
    Anticancer Res; 2002; 22(4):2493-9. PubMed ID: 12174951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic value of p53 and c-erbB-2 expression, proliferative activity and angiogenesis in node-negative breast carcinoma.
    Erdem O; Dursun A; Coşkun U; Günel N
    Tumori; 2005; 91(1):46-52. PubMed ID: 15850004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pleomorphic lobular carcinoma of the breast: its cell kinetics, expression of oncogenes and tumour suppressor genes compared with invasive ductal carcinomas and classical infiltrating lobular carcinomas.
    Frolik D; Caduff R; Varga Z
    Histopathology; 2001 Nov; 39(5):503-13. PubMed ID: 11737309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.